Chang Seong Hwan, Kim Chan Jong
Department of Pediatrics, Chonnam National University Medical School and Children's Hospital, Gwangju, Korea.
Ann Pediatr Endocrinol Metab. 2024 Oct;29(5):316-324. doi: 10.6065/apem.2346234.117. Epub 2024 Oct 31.
Growth hormone (GH) stimulation tests are essential tools for diagnosing GH deficiency (GHD). We aimed to compare L-dopa, insulin, and arginine-induced stimulation tests based on response to GH replacement.
We retrospectively collected data from a review of patients who underwent the GH stimulation test. A total of 138 patients diagnosed with idiopathic short stature were categorized into group I. The remaining 135 patients, who were diagnosed with GHD and treated for 1 year, were classified into 2 subgroups: group IIa, consisting of patients with an increase of at least 0.5 in height standard deviation score (SDS), and group IIb, patients with an increase of less than 0.5 in height SDS.
At the initial visit, group IIa exhibited significantly lower insulin-like growth factor binding protein-3 (IGF-BP3) and higher body mass index (BMI) SDS compared to the other groups. Following 1 year of treatment, group IIb showed significantly lower height SDS, height SDS gain, growth velocity, predicted adult height SDS, weight SDS, and a higher insulin-like growth factor-1 SDS than group IIa. Bone age and IGF-BP3 were inversely associated, and BMI SDS and IGF-BP3 were positively associated with height SDS gain in GHD patients. The specificity and accuracy rates were 50.3% and 70.3% for the L-dopa-induced stimulation test, 72.3% and 86.6% for the insulin tolerance test (ITT), and 64.7% and 87.2% for the arginine-induced stimulation test (ArST).
The ArST demonstrated lower specificity compared to the ITT. However, patients undergoing ArST experienced fewer side effects, suggesting that a careful selection of stimulation tests is crucial in diagnosing GHD.
生长激素(GH)刺激试验是诊断生长激素缺乏症(GHD)的重要工具。我们旨在根据对GH替代治疗的反应比较左旋多巴、胰岛素和精氨酸诱导的刺激试验。
我们回顾性收集了接受GH刺激试验患者的回顾性数据。总共138例诊断为特发性身材矮小的患者被归入第一组。其余135例诊断为GHD并接受1年治疗的患者被分为2个亚组:第二组a,由身高标准差评分(SDS)增加至少0.5的患者组成;第二组b,身高SDS增加小于0.5的患者。
在初次就诊时,与其他组相比,第二组a的胰岛素样生长因子结合蛋白-3(IGF-BP3)显著降低,体重指数(BMI)SDS更高。经过1年治疗后,第二组b的身高SDS、身高SDS增加量、生长速度、预测成人身高SDS、体重SDS均显著低于第二组a,胰岛素样生长因子-1 SDS更高。在GHD患者中,骨龄与IGF-BP3呈负相关,BMI SDS和IGF-BP3与身高SDS增加量呈正相关。左旋多巴诱导刺激试验的特异性和准确率分别为50.3%和70.3%,胰岛素耐量试验(ITT)为72.3%和86.6%,精氨酸诱导刺激试验(ArST)为64.7%和87.2%。
与ITT相比,ArST的特异性较低。然而,接受ArST的患者副作用较少,这表明在诊断GHD时仔细选择刺激试验至关重要。